NDC 64661-793 Biopar Delta-forte

1 Nf Units, 50 Mcg Cbl, 2.5 Mg F-thf, 1 Mg Pteglu-, 7 Mg Me-thf

NDC Product Code 64661-793

NDC CODE: 64661-793

Proprietary Name: Biopar Delta-forte What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: 1 Nf Units, 50 Mcg Cbl, 2.5 Mg F-thf, 1 Mg Pteglu-, 7 Mg Me-thf What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

NDC Code Structure

  • 64661 - Jaymac Pharmacueticals Llc

NDC 64661-793-30

Package Description: 30 BLISTER PACK in 1 CARTON > 1 CAPSULE in 1 BLISTER PACK

NDC Product Information

Biopar Delta-forte with NDC 64661-793 is a a human prescription drug product labeled by Jaymac Pharmacueticals Llc. The generic name of Biopar Delta-forte is 1 nf units, 50 mcg cbl, 2.5 mg f-thf, 1 mg pteglu-, 7 mg me-thf. The product's dosage form is capsule and is administered via oral form.

Labeler Name: Jaymac Pharmacueticals Llc

Dosage Form: Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Biopar Delta-forte Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • INTRINSIC FACTOR 50 mg/1
  • COBALAMIN 50 ug/1
  • COBAMAMIDE 50 ug/1
  • LEVOLEUCOVORIN 2.5 mg/1
  • DIHYDROFOLIC ACID 1 mg/1
  • LEVOMEFOLATE MAGNESIUM 7 mg/1

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • FERROUS CYSTEINE GLYCINATE (UNII: 8B4OP7RK5N)
  • 1,2-DOCOSAHEXANOYL-SN-GLYCERO-3-PHOSPHOSERINE CALCIUM (UNII: 6WJM73T46K)
  • 1,2-ICOSAPENTOYL-SN-GLYCERO-3-PHOSPHOSERINE CALCIUM (UNII: 9ABD9DRK7B)
  • PHOSPHATIDYL SERINE (UNII: 394XK0IH40)
  • PYRIDOXAL PHOSPHATE ANHYDROUS (UNII: F06SGE49M6)
  • FLAVIN ADENINE DINUCLEOTIDE (UNII: ZC44YTI8KK)
  • NADH (UNII: 4J24DQ0916)
  • COCARBOXYLASE (UNII: Q57971654Y)
  • MAGNESIUM ASCORBATE (UNII: 0N1G678593)
  • ZINC ASCORBATE (UNII: 9TI35313XW)
  • RIBOFLAVIN (UNII: TLM2976OFR)
  • MAGNESIUM L-THREONATE (UNII: 1Y26ZZ0OTM)
  • BETAINE (UNII: 3SCV180C9W)
  • CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
  • SODIUM CITRATE (UNII: 1Q73Q2JULR)
  • ANNATTO (UNII: 6PQP1V1B6O)
  • GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
  • GLYCERIN (UNII: PDC6A3C0OX)
  • LECITHIN, SUNFLOWER (UNII: 834K0WOS5G)
  • OLIVE OIL (UNII: 6UYK2W1W1E)
  • PIPERINE (UNII: U71XL721QK)
  • WATER (UNII: 059QF0KO0R)
  • UBIDECARENONE (UNII: EJ27X76M46)
  • YELLOW WAX (UNII: 2ZA36H0S2V)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.
  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Folate Analog - [EPC] (Established Pharmacologic Class)
  • Folic Acid - [CS]

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Jaymac Pharmacueticals Llc
Labeler Code: 64661
Marketing Category: UNAPPROVED DRUG OTHER - What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 09-01-2020 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Biopar Delta-forte Product Label Images

Biopar Delta-forte Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Description

[1 NF Units] [50 mcg CBl] [2.5 mg F-THf] [1 mg PteGlu-] [7 mg Me-THf]   Prescription Hematopoietic Preparation For Therapeutic Use   Multiphasic Softgels (30ct carton)   NDC 64661-793-30   Rx ONLY   BioparTMdelta-FORTE is an orally administered prescription hematopoietic preparation for therapeutic use formulated for adult macrocytic anemia patients – specifically including pernicious anemia patients, ages 12 and up, who are under specific direction and monitoring of cobalamin and folate status by a physician. A recent study+ suggested that BioparTM delta-FORTE was effective in lowering homocysteine levels in patients that are positive for MTHFR (methylenetetrahydrofolate reductase polymorphism). BioparTM delta-FORTE may be taken by women of childbearing age. BioparTM delta-FORTE may be taken by geriatric patients where compliance is an issue.    + ClinicalTrials.gov identifier: NCT02709668, Correlation of Clinical Response With Homocysteine Reduction During Therapy With Reduced B Vitamins in Patients with MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism.

Ingredients

Cobalamin-intrinsic factor concentrate (non-inhibitory)1 .............................................................................................. 1 NF Units§   Adenosylcobalamin (coenzyme B12) .............................................................................................................................. 50 mcg   Formyl folic acid, L-FTHf .............................................................................................................................................. 2.5 mg2   Reduced folic acid, DHf- ................................................................................................................................................. 1 mg2   Methyl folic acid, L-MeTHf ............................................................................................................................................... 7 mg2      1 50 mcg Vitamin B12 (activity equivalent) and 50 mg of intrinsic factor concentrate§ from ultra-purified, porcine-derived stomach substance from a porcine, disease-free country; together these equal 1 NF Units. Cobalamin has hematopoietic activity apparently identical to that of the anti-anemia factor in purified liver-stomach extract      2 15 mg DFE DeltaFolate™ (total folates) of which 9 mg DFE is from l-methylfolate magnesium (molar equivalent) from amorphous, diastereoisomerically pure l-methylfolate (less than 1% d-isomer)

Inactives

FUNCTIONAL EXCIPIENTS:      25 mg ascorbates4a (24 mg magnesium l-ascorbate, 1 mg zinc l-ascorbate) [antioxidant], 13.6 mg chelates (FeGC3 as ferrous glycine cysteinate subsisting of 1.5 mg elemental iron4a) [colorant].OTHER EXCIPIENTS:       Annatto [colorant], betaine (trimethylglycine) [acidifier], citrates (citric acid, sodium citrate) [stabilizers], flavin adenine dinucleotide (B2-vitamer)4b, gelatin (bovine), glycerine, nicotinamide adenine dinucleotide hydride (B3-vitamer)4b, phospholipids (sunflower lecithin, phosphatidylserine-docosahexaenoic acid complex5) [emulsifiers], piperine [bioavailability enhancer], purified water, pyridoxal 5’ phosphate (B6-vitamer)4b, thiamine pyrophosphate (B1-vitamer)4b, ubidecarenone [antioxidant], yellow beeswax.      3 Pure amino acid, cysteinated iron chelate as AminoFerTM under exclusive license by Viva Pharmaceuticals, Canada, U.S. Patent #7341708      4a 30% daily value (DV) of VITAMIN C, and 10% DV IRON for geriatric patients.      4b Contains less than 2% (<25 mcg/each) of vitamins B1, B2, B3 and B6.      5 Contains at least 12 mg phosphatidylserine (PS) – of which approximately 6.4 mg as PS-DHA, and less than 1% EPA (<800 mcg PS-EPA)

Contains

FISH/KRILL/PORCINE (Intrinsic Factor/Cobalamin)/SOY   Certified 3rd-party GLUTEN-FREE. No artificial colorants. No dairy, wheat, sugar or egg

Indications & Usage

BioparTMdelta-FORTE is indicated in the treatment of pernicious anemia and the prevention of folate deficiency;   BioparTM delta-FORTE is specifically indicated as a primary and adjunctive treatment in pernicious anemia patients having idiosyncrasy or sensitivity to parenteral administration - or when parental therapy is refused;   BioparTM delta-FORTE is further indicated in the maintenance of normal hematologic status (hematopoiesis) in macrocytic anemia conditions which are caused by either cobalamin and/or folate deficiency, and where increased intrinsic factor is desired - including:      1. Malabsorption of cobalamin resulting from structural or functional damage to the stomach - where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates cobalamin absorption. Folate deficiency in these patients is usually more severe than cobalamin deficiency;      2. Genetic polymorphisms such as MTHFR that impede folate metabolism and the effective use of synthetic folic acid (oxidized form); and      3. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces cobalamin deficiency. Structural lesions leading to cobalamin deficiency include regional ileitis, ileal resections, malignancies, etc

Mechanism Of Action

COBALAMIN [treatment]; FOLATE [prevention]; INTRINSIC FACTOR [facilitator] -Cobalamin is essential for the synthesis of methionine from homocysteine - a reaction which also requires folate. In the absence of cobalamin - ie, cobalamin deficiency, tetrahydrofolate cannot be regenerated from l-methylfolic acid, and a functional folate deficiency occurs - ie, “methyl trap hypothesis”. Gastrointestinal absorption of cobalamin depends on the presence of sufficient intrinsic factor, and lack of intrinisic factor results in cobalamin deficiency.

Dosage & Administration

The adult dose is one capsule daily preferably on an empty stomach.   A deficiency of cobalamin may present first as folate deficiency - which is why folate supplementation may mask the symptoms that would normally result and also why advanced folate supplementation requires licensed medical supervision; because of this, reticulocyte plasma count, cobalamin and folate must be obtained prior to treatment. Requirements of cobalamin and/or folate in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation.    As a general rule - in Pernicious Anemia patients, treatment will be required for the remainder of the patient’s life, and usually requires weekly or monthly injections at the doctor's office. Patients that are non-compliant with parenteral therapy (injections) may use this product as a substitute ONLY UNDER THE DIRECT SUPERVISION OF A LICENSED MEDICAL PRACTITIONER.

Adverse Reactions

Mild transient diarrhea, polycythemia vera, itching, transitory exanthema, feeling of swelling of entire body may occur with administration of cobalamin. Allergic sensitization has been reported following both oral and parenteral administration of folate.   Sensitivity to porcine intrinsic factor derived from liver substance has been reported in patients, and may occur at any time; BioparTMdelta-FORTE contains a non-inhibitory form of intrinsic factor that is not derived from liver substance but rather just the mucosa (stomach substance) - in which such senstitivity is less likely to occur, however caution is advised and continuous monitoring under licensed medical supervision is required.

Warning

USE OF THIS PRODUCT WITHOUT DIRECT SUPERVISION OF A PHYSICIAN IS DANGEROUS;Some patients afflicted with pernicious anemia may or not respond to the orally ingested vitamin B12, and there is no known way to predict which patients may respond and which patients may cease to respond;Periodic examinations and laboratory studies of pernicious anemia patients are essential and recommended; and -The parenteral administration of (cyano)cobalamin - or vitamin B12, is generally recognized as a fully effective treatment of pernicious anemia. Parenteral alkyl-cobalamin preparations have not been and are not authorized for use except by or on the prescription of a physician.

Precautions

GENERAL:      0.1 mg or more of folic acid daily may obscure pernicious anemia in that the hematological remission may occur while neurological manifestations remain progressive. The safe tolerable limit for folic acid (in preparations) is 1 mg [emphasis added];      Folic acid is not a substitute for vitamin B12 - although it may improve vitamin B12-deficient anemias. Exclusive use of folic acid in treating vitamin B12-deficient anemias could result in progressive and irreversible neurologic damage. Specifically, vitamin B12 deficiency allowed to progress over 3 months may produce permanent degenerative lesions of the spinal cord - as observed when folate therapy is used as the only hematopoietic agent;      Doses of vitamin B12 exceeding 10 mcg daily may produce hematologic response in patients with folate deficiency. Indiscriminate administration may mask the true diagnosis; and -      A dietary deficiency of only vitamin B12 is rare; multiple vitamin deficiency is expected in any dietary deficiency. No single regimen fits all cases, and the status of the patient observed in follow-up is the final criterion for adequacy of therapy.DRUG INTERACTIONS:      Colchicine, para-aminosalicylic acid, and heavy alcohol intake for longer than 2 weeks may produce malabsorption of cobalamin.      Epileptic, antineoplastic and Parkinson's medications are cautioned in the concimant use with folate supplementation.

How Supplied

BioparTM delta-FORTE is supplied as oval, annatto (”orangish-brown”) multiphasic softgels* with imprint "7N3". Provided as a carton with 30 softgels in blister cards. NDC 64661-793-30.

Regulatory

BioparTMdelta-FORTE is regulated as a drug to ensure it's use is under medical supervision, and because of this, advanced folate supplementation is possible [21 CFR 250.201].

Storage And Handling

Call your medical practitioner about side effects. You may report side effects by calling (337) 662-5962.   KEEP THIS OUT OF THE REACH OF CHILDREN.   (Tamper Evident: Do not use if seal is broken or missing)Do not exceed the recommended dose.   STORAGE: Store at 20 ̊-25 ̊ C (68 ̊-77 ̊ F)   CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT A PRESCRIPTION   [Rx ONLY]PATENTS: Patent(s) pending.TRADEMARKS: BioparTMdelta-FORTE is a registered mark of JayMac Pharmaceuticals. DeltaFolateTM is a use-trademark of Jaymac Pharmaceuticals.   JAYMAC Pharmaceuticals, LLC   Sunset, LA 70584   MANUFACTURED AND/OR PACKAGED IN USA/CANADA   Revision   August 26, 2020

* Please review the disclaimer below.